Literature DB >> 20159976

Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine.

Julie R Field1, L Keith Henry, Randy D Blakely.   

Abstract

The plasma membrane serotonin (5-HT) transporter (SERT, SLC6A4) clears 5-HT after release at nerve termini and is targeted by both antidepressant medications and psychostimulants (e.g. MDMA, cocaine). Homology modeling of human SERT (hSERT), based on high resolution structures of the microbial SLC6 family member LeuT(Aa), along with biochemical studies of wild type and mutant transporters, predicts transmembrane (TM) domains 1, 3, 6, and 8 comprise the 5-HT-binding pocket. We utilized the substituted cysteine accessibility method along with surface and site-specific biotinylation to probe TM6 for aqueous accessibility and differential interactions with 5-HT and psychostimulants. Our results are consistent with TM6 being composed of an aqueous-accessible, alpha-helical extracellular domain (TM6a) that is separated by a central, unwound section from a cytoplasmically localized domain (TM6b) with limited aqueous accessibility. The substitution G338C appears to lock hSERT in an outward-facing conformation that, although accessible to aminoethylmethanethiosulfonate-biotin, 5-HT, and citalopram, is incapable of inward 5-HT transport. Transport of 5-HT by G338C can be partially restored by the TM1 mutation Y95F. With regard to methanethiosulfonate (MTS) inactivation of uptake, TM6a Cys mutants demonstrate Na(+)-dependent [2-(trimethylammonium)ethyl]-MTS sensitivity. Studies with the centrally located substitution S336C reveal features of a common binding pocket for 5-HT and 3,4-methylenedioxymethamphetamine (MDMA). Interestingly, the substitution I333C reveals an MDMA-induced conformation not observed with 5-HT. In the context of prior studies on TM1, our findings document shared and unique features of TM6 contributing to hSERT aqueous accessibility, ligand recognition, and conformational dynamics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159976      PMCID: PMC2857005          DOI: 10.1074/jbc.M109.093658

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  The role of external loop regions in serotonin transport. Loop scanning mutagenesis of the serotonin transporter external domain.

Authors:  Y Smicun; S D Campbell; M A Chen; H Gu; G Rudnick
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion.

Authors:  H H Sitte; B Hiptmair; J Zwach; C Pifl; E A Singer; P Scholze
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment.

Authors:  H Hastrup; A Karlin; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

4.  Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study.

Authors:  H H Sitte; P Scholze; P Schloss; C Pifl; E A Singer
Journal:  J Neurochem       Date:  2000-03       Impact factor: 5.372

5.  Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.

Authors:  E M Adkins; E L Barker; R D Blakely
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

6.  The yeast mitochondrial citrate transport protein. Probing the secondary structure of transmembrane domain iv and identification of residues that likely comprise a portion of the citrate translocation pathway.

Authors:  R S Kaplan; J A Mayor; D Brauer; R Kotaria; D E Walters; A M Dean
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

7.  A competitive inhibitor traps LeuT in an open-to-out conformation.

Authors:  Satinder K Singh; Chayne L Piscitelli; Atsuko Yamashita; Eric Gouaux
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

8.  Flux coupling in the human serotonin transporter.

Authors:  Scott V Adams; Louis J DeFelice
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

9.  Accessibility and conformational coupling in serotonin transporter predicted internal domains.

Authors:  Andreas Androutsellis-Theotokis; Gary Rudnick
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

10.  Oligomerization of serotonin transporter and its functional consequences.

Authors:  F Kilic; G Rudnick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  18 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

2.  Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113.

Authors:  Erik R Hill; Xiaoqin Huang; Chang-Guo Zhan; F Ivy Carroll; Howard H Gu
Journal:  Neuropharmacology       Date:  2011-03-21       Impact factor: 5.250

3.  Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.

Authors:  Brent J Thompson; Tammy Jessen; L K Henry; Julie R Field; Karen L Gamble; Paul J Gresch; Ana M Carneiro; Rebecca E Horton; Peter J Chisnell; Yekaterina Belova; Douglas G McMahon; Lynette C Daws; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

4.  A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport.

Authors:  L Keith Henry; Hideki Iwamoto; Julie R Field; Kristian Kaufmann; Eric S Dawson; Miriam T Jacobs; Chelsea Adams; Bruce Felts; Igor Zdravkovic; Vanessa Armstrong; Steven Combs; Ernesto Solis; Gary Rudnick; Sergei Y Noskov; Louis J DeFelice; Jens Meiler; Randy D Blakely
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

5.  Structures of LeuT in bicelles define conformation and substrate binding in a membrane-like context.

Authors:  Hui Wang; Johannes Elferich; Eric Gouaux
Journal:  Nat Struct Mol Biol       Date:  2012-01-15       Impact factor: 15.369

6.  4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.

Authors:  Ernesto Solis; Igor Zdravkovic; Ian D Tomlinson; Sergei Y Noskov; Sandra J Rosenthal; Louis J De Felice
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

Review 7.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

8.  Comparative modeling of the human monoamine transporters: similarities in substrate binding.

Authors:  Heidi Koldsø; Anja B Christiansen; Steffen Sinning; Birgit Schiøtt
Journal:  ACS Chem Neurosci       Date:  2012-11-08       Impact factor: 4.418

9.  Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridge.

Authors:  Jon D Gaffaney; Madhur Shetty; Bruce Felts; Akula-Bala Pramod; James D Foster; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2013-11-20       Impact factor: 3.921

10.  Extracellular loop 3 of the noradrenaline transporter contributes to substrate and inhibitor selectivity.

Authors:  Timothy Lynagh; Tina S Khamu; Lesley J Bryan-Lluka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-10-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.